Observational studyRheumatology international2025
Demographics and clinical manifestations in patients with Behçet's disease: a retrospective observational study from a non-endemic country.
Observational study in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Correlation analysis of cytokine levels and peripheral blood T lymphocyte subsets in systemic vascular inflammatory disease.Journal of medical biochemistry · 2026Article
- Optimizing anti-TNF therapy in Behçet's disease: the role of therapeutic drug monitoring.Frontiers in immunology · 2026Review
- High prevalence of HLA-B51 and ocular involvement in Behçet's disease: a multicenter cross-sectional study.Rheumatology international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's disease (BD) is a systemic vasculitis of unknown origin affecting both arterial and venous vessels, resulting in diverse clinical features. Its manifestations vary due to ethnic, geographic, and individual differences. Although the highest prevalence of BD is reported along the ancient Silk Road route, nowadays, due to population migrations, the disease can be detected worldwide. Our study aimed to evaluate the demographic and clinical characteristics of patients with BD in a cohort from a non-endemic country and compare it with other cohorts from endemic and non-endemic countries worldwide. Our retrospective observational case-series study included the data from a single Rheumatology centre. We analyzed the data from 38 patients (17 men and 21 women) with a mean age at diagnosis of 29 years ± SD 8.87 and with a mean follow-up of 12.7 years. The most common manifestations were oral (97.4%) and genital ulcerations (73.7%), skin (57.9%) and ophthalmological changes (63.1%). Other clinical manifestations, musculoskeletal (42.1%), vascular (18.4%), neurological (15.8%) and gastrointestinal (15.8%) were less common. HLA-B51 frequency was 51.5%, without significant difference between females and males (10:7 cases). All patients were treated with local therapy, while systemic glucocorticoids were given in 84.2%, followed by colchicine in 44.7%. Immunosuppressive / immunomodulator therapy (most common azathioprine) was administered in 68.4% of patients. Due to disease severity, 13.2% of patients required biological TNF- inhibitor. Although BD is most prevalent in endemic countries, the disease can be diagnosed worldwide. Due to the disease's complex pathogenesis, its varied presenting manifestations, and the lack of pathognomonic signs and symptoms, diagnosis can be delayed in non-endemic countries, leading to the untimely initiation of targeted treatment.
Indexed as
Identifiers
40232346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.